The Quigley Lab studies tumor genomes to understand how urological cancers develop and respond to therapy.
We address questions of broad importance in cancer therapy and tumor biology: how and when does resistance to
targeted therapy arise? How does genome evolution across distinct metastases affect the course of disease? How do
variants in the non-coding genome affect therapy response? We are particularly focused on understanding how to detect and overcome resistance to PARP inhibitor and androgen-targeted
therapy in advanced prostate cancer, a disease that is uniformly fatal.
Our lab is part of the Department of Urology
Helen Diller Family Comprehensive Cancer Center
University of California, San Francisco
Circos plots of prostate tumor genomes with BRCA2,
CDK12, and TP53 inactivation